Major Neurologic Adverse Drug Reactions, Potential Drug–Drug Interactions and Pharmacokinetic Aspects of Drugs Used in COVID-19 Patients with Stroke: A Narrative Review

Parisa Ghasemiyeh, Afshin Borhani-Haghighi, Iman Karimzadeh, Soliman Mohammadi-Samani, Afsaneh Vazin, Anahid Safari, Adnan I Qureshi

Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; Pharmaceutical Sciences Research Center, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; Clinical Neurology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Department of Pharmaceutics, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran; Stem Cells Technology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran; Zeenat Qureshi Stroke Institute and Department of Neurology, University of Missouri, Columbia, MO, USA

Abstract: Stroke has been considered as one of the underlying diseases that increases the probability of severe infection and mortality. Meanwhile, there are ongoing reports of stroke subsequent to COVID-19 infection. In this narrative paper, we reviewed major neurologic adverse drug reactions (ADRs) and pharmacokinetics of drugs which are routinely used for COVID-19 infection and their potential drug–drug interactions (PDDIs) with common drugs used for the treatment of stroke. It is highly recommended to monitor patients on chloroquine (CQ), hydroxychloroquine (HCQ), antiviral drugs, and/or corticosteroids about initiation or progression of cardiac arrhythmias, delirium, seizure, myopathy, and/or neuropathy. In addition, PDDIs of anti-COVID-19 drugs with tissue plasminogen activator (tPA), anticoagulants, antiaggregants, statins, antihypertensive agents, and iodine-contrast agents should be considered. The most dangerous PDDIs were interaction of lopinavir/ritonavir or atazanavir with clopidogrel, prasugrel, and new oral anticoagulants (NOACs).

Keywords: SARS-CoV-2, COVID-19, stroke, potential drug–drug interactions, adverse drug reactions, pharmacokinetics

Introduction

The coronavirus disease 2019 (COVID-19) pneumonia pandemic has spread all over the globe with considerable morbidity and mortality. The severe disease might occur in healthy individuals of any age, but it mostly occurs in adults with older age or predisposing medical comorbidities such as heart disease, diabetes mellitus (DM), hypertension (HTN), chronic lung disease, neoplasm, chronic renal failure.

More than one-third of patients who required intensive care unit (ICU) admission had at least one underlying vascular risk factor. In addition to respiratory symptoms, COVID-19 can also lead to hematological and cardiac complications. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been reported to be associated with myocarditis, and cardiac arrhythmias. Meanwhile, there are reports of hypercoagulable state in COVID-19 infection. There are also reports of increased D-dimer and fibrin degradation products (FDP) in patients with COVID-19 infection, particularly those with severe disease.

Apart from the respiratory system as the predominant target of the virus, angiotensin-converting enzyme 2 (ACE2) receptor, a key cell surface protein facilitating COVID-19 entry to the cells, is found in various cells including vascular endothelium...
and neurons. The possible association between stroke and SARS-CoV-2 infection appears to be complex and bidirectional. Stroke has been considered as one of the underlying diseases that increase the probability of severe infection and mortality. Among cases with fatalities, 15.4% had cerebral infarction. Up to 11% of hospitalized patients with COVID-19 infection suffer from stroke. The reported mortality is much higher in individuals with both COVID-19 infection and stroke than that observed in patients with stroke who do not have COVID-19 infection. There are ongoing reports of stroke subsequent to COVID-19 infection. In an unpublished report from China, acute ischemic stroke, cerebral venous sinus thrombosis, and intracerebral hemorrhage were observed in 11, 1, and 1 out of 221 COVID-19 patients, respectively. In patients with ischemic stroke, 6 took aspirin or clopidogrel and 5 received enoxaparin. In another Chinese case report, 3 patients with COVID-19 infection and multiple infarcts were reported. The authors considered coagulopathy and antiphospholipid antibodies as the major contributing factors.

Medication errors (MEs) and adverse drug reactions (ADRs) are among the major causes of morbi-mortality in the medical wards and ICUs. Potential drug–drug interactions (PDDIs) are among the preventable causes of MEs. Considering suitable alternative drugs, dose modification, and monitoring clinical presentations of ADRs by doctors and clinical pharmacists may decrease PDDIs. It has been shown that PDDIs are common among hospitalized patients in the neurology wards, especially among those receiving multiple medications. In this narrative paper, we reviewed major neurologic ADRs, the pharmacokinetics of medications with potential anti-COVID-19 activity, and their PDDIs with common drugs used for the treatment of stroke.

Search Strategy
Literature were searched on Pubmed, Scopus, Google Scholar, and Web of Science databases using the key search terms COVID-19, SARS-CoV-2, neurologic ADRs, stroke, cerebrovascular disease, and PDDIs from 1971 until April 2020. In this regard, first titles and abstracts of peer-reviewed articles were reviewed. This search strategy was limited to human studies that were published in the English language.

Pharmacokinetics
COVID-19 infection and stroke both have a relatively high risk of renal impairment and perhaps even show higher risk when both occur together. In a prospective cohort project on 701 patients with COVID-19 pneumonia infection, acute kidney injury (AKI) was observed in 5.1% of hospitalized patients. The rate of AKI was much higher than the 1–2% rate reported among all hospitalizations in China. AKI is also relatively common and seen in 10% of patients with ischemic stroke and 20% of patients with hemorrhagic stroke.

According to Table 1, suitable drug selection should be considered especially in COVID-19 patients with the predisposing disease based on pharmacokinetic aspects of drugs. For example, umifenovir which is mainly metabolized via liver should be used with caution in patients with underlying hepatic disease.

Since chloroquine (CQ) and hydroxychloroquine (HQC) have a narrow therapeutic index and toxicity could be occurred with cardiovascular events, these agents should be used with caution in patients with underlying cardiovascular disease. CQ in patients who are consuming heparin could enhance the risk of bleeding. Also, CQ in patients who are on digoxin could cause cardiac block.

Adverse Drug Reactions (ADR)
Potential drugs which are used in COVID-19 pneumonia management have many neurologic ADRs, some of these most important adverse events are listed in Table 2.

Major Neurologic Adverse Drug Reactions (ADRs)
Chloroquine (CQ)/Hydroxychloroquine (HCQ) ADRs
Extrapyramidal Reactions
There are several reports of CQ/HQC-induced Parkinsonism, oculogyric crisis, and dystonias. Another report revealed that extrapyramidal syndrome might also occur after the administration of a single standard dose of CQ.

Hallucination and Psychosis
Previous studies revealed that CQ could induce psychotic features such as mood disorder (mixed episode), irritability, anxiety, agitation, and blunted mood. These psychotic features were more common accompanied by positive symptoms, hallucination, and derealization. Also, results revealed that the severity of these hallucinations and psychotic features are not dose-dependent.

Seizure
Several studies revealed that CQ consumption could induce seizures. It has been suggested that CQ-induced seizure is an idiosyncratic adverse effect.
Table 1 A Brief Pharmacokinetic Data of Potential Drugs Used in COVID-19 Management

| Anti-COVID-19 Agent | Bioavailability (F) | Volume of Distribution (Vd) | Elimination half-life (T ½) | Clearance (Cl) | Distribution | Metabolism | Route of Elimination |
|---------------------|---------------------|-----------------------------|-----------------------------|----------------|-------------|-----------|----------------------|
| Chloroquine (CQ)    | 67–114%             | 200–800 L/kg               | 20 to 60 days               | 0.35–1 L/h/kg  | Wide distribution to many body tissues containing the heart, kidneys, liver, eyes, leukocytes, and lungs. It could obtain prolonged deposition in the lungs. | Partially hepatic to the main metabolite, desethylchloroquine. Metabolized by CYP2C8, CYP3A4, and to a lesser extent CYP2D6. | Predominantly eliminated in the urine. |
| Hydroxy chloroquine (HCQ) | 67–74% | 63 L/kg | 20 to 120 days | 5.76 L/h | In comparison with chloroquine, it has a more limited distribution to body tissues. | Hepatic; metabolites include bidesethylchloroquine, desethylhydroxychloroquin, and desethylchloroquine. Metabolized by CYP2C8, CYP3A4, and to a lesser extent CYP2D6. | 40–50% is excreted renally. |
| Lopinavir           | 25%                 | 1–1.5 L/kg                 | 6.9 ± 2.2 hours             | 6–7 L/h       | It could be distributed to body tissues except the brain. | Hepatic via CYP3A4: 13 metabolites identified; may induce its own metabolism. | Primarily eliminated in the feces (82.6 ± 2.5%) and the remaining excreted in the urine. |
| Ritonavir           | Variable; increased with food. | 0.41 ± 0.25 L/kg | 3 to 5 hours | 8.8 ± 3.2 L/h | It could obtain a high concentration in plasma and lymph nodes but limited distribution to body tissues. | Hepatic via CYP3A4 and 2D6; five metabolites, low concentration of an active metabolite (M-2) achieved in plasma (oxidative). | Primarily eliminated in the feces (86.4 ± 2.9%) and the remaining excreted in the urine. |
| Atazanavir          | 60–68%; enhanced with food. | 1.4 L/kg | 7 hours (increased to 12 hours in hepatically impaired patients) | 9.4 L/h | It has a highly variable distribution into body fluids. | Hepatic metabolism via CYP3A, also undergoes biliary elimination. | Primarily eliminated in the feces (79%) |
| Interferon-alpha IM: 83%; SubQ: 90% | 1.4 L/kg | 2 to 3 hours | 0.231 L/h/kg | It has wide distribution to body tissues especially in patients with leukemia (up to 20-folds). Interferon alpha could not penetrate CSF. | Primarily renal, filtered and absorbed at the renal tubule | Renal clearance |
| Umifenovir Rapid absorption | Not available | 17 to 21 hours | 99 ± 34 L/h | It has rapid absorption and distribution to different organs and tissues. | Mainly metabolized by the liver, it should be used with caution in patients with liver dysfunction. | The major route of elimination is via the feces |

(Continued)
| Anti-COVID-19 Agent | Bioavailability (F) | Volume of Distribution (Vd) | Elimination half-life (T ½) | Clearance (Cl) | Distribution | Metabolism | Route of Elimination |
|---------------------|---------------------|-----------------------------|-----------------------------|----------------|-------------|------------|---------------------|
| Favipiravir         | 97.6%               | 11–13.7 L/kg                | 2 to 5.5 hours              | 2.98±0.30 L/h | It may present rapid uptake and clearance from the liver, kidneys, and intestine during first dose administration. But in multiple-dose administration, plasma concentration may be diminished while drug distribution and accumulation in the liver, stomach, and brain would be enhanced significantly. | A genetic variant in digestive transport [Pgpk; ABCB1] and metabolism [aldehyde oxidase] to an inactive M1, urinary excretion; both metabolized by and inhibited by aldehyde oxidase | Predominantly renal clearance |
| Remdesivir          | Not available       | Not available               | 0.39 hour                   | Not available | It has rapid distribution in PBMCs and conversion to its active form. | Predominantly metabolized to a triphosphate metabolite. | Not available |
| Tocilizumab         | SubQ: 80%           | 0.054 L/kg                  | Concentration-dependent; up to 16 days | Concentration-dependent; Mean: 0.29 ± 0.10 mL/h/kg | It might distribute to lymphatic, hematopoietic, digestive, endocrine, muscular, neural, respiratory, urinary systems, etc. Vd in adults is up to 2-folds in children. | Not available | Biphasic elimination from the circulation |
| Ivermectin          | Well absorbed; Improved absorption with high fat meal. | 3 to 3.5 L/kg               | 16 to 18 hours              | 1.2 L/h | It may obtain high drug concentration in liver and adipose tissues, but has poor penetration through blood brain barrier. | Primarily hepatic metabolism. | Metabolized in the liver; ivermectin and/or its metabolites are excreted almost exclusively in the feces, Urine (<1%) |
| Teicoplanin         | Oral: poorly absorbed IM: 90% | 0.86 L/kg | 70 to 100 hours | 0.0033 L/h/kg | Tissue distribution of teicoplanin is highly variable. It may present extensive distribution to liver tissue but poor penetration into CSF. | Metabolic transformation due to hydroxylation in the omega-2 and omega-1 positions for metabolites 1 and 2, respectively, of the C-10 linear side chain of component A2-3. | Not available |

(Continued)
Myopathy. Myopathy related to CQ/HCQ consumption is a type of reversible vacuolar myopathy. Clinical presentation of this myopathy is very non-selective and patients may experience a mild to moderate muscle weakness, which may also be a common presentation of COVID-19 and creatinine kinase (CK) elevation. This myopathy is poorly related to the dose or duration of CQ/HCQ therapy but it might be related to the predisposing connective tissue disorders and long-term corticosteroid consumption. Other potential risk factors of CQ/HCQ-induced myopathy are renal failure, Caucasian ethnicity, and co-administration of statins, proton pump inhibitors, and other myotoxic agents.

Arrhythmia and Cardiac Reactions. It has been reported that CQ/HCQ could induce heart failure, cardiac conductive disorders, and hypertrophic cardiomypathy which are reversible and could be recovered after discontinuation of therapy. It seems that these cardiac reactions are dose-dependent and also more common in patients with underlying renal failure.

CQ and HCQ (less likely) could also be associated with QT-prolongation and QT-related malignant arrhythmias. Both

### Table 1 (Continued)

| Anti-COVID-19 Agent | Bioavailability (F) | Volume of Distribution (Vd) | Elimination half-life (T ½) | Clearance (Cl) | Distribution | Metabolism | Route of Elimination |
|---------------------|---------------------|-----------------------------|-----------------------------|----------------|-------------|------------|----------------------|
| Azithromycin        | 37%                 | 31.1 L/kg                   | 68 hours                    | 37.8 L/h       | Extensively distributed to body tissues including skin, tonsil, lungs, sputum, etc. but has poor distribution to brain tissues due to limited CSF penetration. | Hepatic metabolism to inactive metabolites | Biliary excretion (major route) Urine (<6%) |
| Hydroxychloroquine  |                     |                             |                             |                |             |            |                      |
| (HCQ)               |                     |                             |                             |                |             |            |                      |
| Umifenovir          |                     |                             |                             |                |             |            |                      |
| Lopinavir/Ritonavir |                     |                             |                             |                |             |            |                      |
| Interferon alpha    |                     |                             |                             |                |             |            |                      |
| Favipiravir         |                     |                             |                             |                |             |            |                      |
| Remdesivir          |                     |                             |                             |                |             |            |                      |
| Tocilizumab         |                     |                             |                             |                |             |            |                      |
| Corticosteroids     |                     |                             |                             |                |             |            |                      |

Notes: *Cytchrome P450 (CYP) 2C8. *Cerebrospinal fluid. *P-glycoprotein. *ATP-binding cassette sub-family B member 1. *Peripheral blood mononuclear cells.

### Table 2 The Common Central Nervous System (CNS) and Peripheral Nervous System (PNS) Adverse Effects of Drugs Used in COVID-19 Management

| Drug                  | CNS Adverse Reactions                                                                 | PNS Adverse Reactions                                                                 |
|-----------------------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------|
| Chloroquine (CQ)      | Acute confusional state, delirium, decreased deep tendon reflex, depression, extrapyramidal disorders, seizure | Myopathy, neuromuscular disease, polyneuropathy                                         |
| Hydroxychloroquine (HCQ) | Ataxia, vertigo, dizziness, sensorineural hearing loss, neurosis, psychosis, seizure | Myopathy                                                                                      |
| Umifenovir            | Dizziness, psychiatric symptoms (0.83%)                                              | Weakness, myalgia                                                                        |
| Lopinavir/Ritonavir   | Fatigue, headache, anxiety (4%), insomnia                                            | Myalgia, asthenia, musculoskeletal pain, arthralgia, back pain                         |
| Interferon alpha      | Fatigue, headache, depression, drowsiness (1 to 33%), dizziness, vertigo, malaise, paresthesia, confusion (≤12), insomnia | Myalgia, asthenia, musculoskeletal pain, arthralgia, back pain                         |
| Favipiravir           | Psychiatric reactions (1.72%)                                                        | Have not reported yet.                                                                   |
| Remdesivir            | Have not reported yet.                                                                | Have not reported yet.                                                                   |
| Tocilizumab           | Headache, dizziness (rare)                                                           | Chronic inflammatory demyelinating polyneuropathy (<1%)                                 |
| Corticosteroids       | Psychosis (14%), mania (28%), depression (41%), delirium, anxiety, insomnia, seizure, vertigo, paresthesia, pseudotumor cerebri | Myopathy, neuropathy                                                                  |

Myopathy, Myopathy related to CQ/HCQ consumption is a type of reversible vacuolar myopathy. Clinical presentation of this myopathy is very non-selective and patients may experience a mild to moderate muscle weakness, which may also be a common presentation of COVID-19 and creatinine kinase (CK) elevation. This myopathy is poorly related to the dose or duration of CQ/HCQ therapy but it might be related to the predisposing connective tissue disorders and long-term corticosteroid consumption. Other potential risk factors of CQ/HCQ-induced myopathy are renal failure, Caucasian ethnicity, and co-administration of statins, proton pump inhibitors, and other myotoxic agents. Arrhythmia and Cardiac Reactions. It has been reported that CQ/HCQ could induce heart failure, cardiac conductive disorders, and hypertrophic cardiomypathy which are reversible and could be recovered after discontinuation of therapy. It seems that these cardiac reactions are dose-dependent and also more common in patients with underlying renal failure.

CQ and HCQ (less likely) could also be associated with QT-prolongation and QT-related malignant arrhythmias. Both
CQ and HCQ, which are potential agents in COVID-19 management, are metabolized through CYP3A4. In COVID-19 management, if CQ or HCQ administered in combination with antiviral agents (such as lopinavir/ritonavir, atazanavir, remdesivir) or azithromycin which are CYP3A4 inhibitors, the risk of QT-prolongation and drug-induced cardiac death would be enhanced.\(^{50,51}\)

**Maculopathy and Retinopathy.** Maculopathy and retinopathy are dose-dependent adverse effects of CQ, especially in the elderly groups, which could be enhanced due to the drug accumulation process. These side effects are more common in total daily doses of over 4 mg/kg/day.\(^{52}\) Since the duration of CQ/HCQ therapy; in COVID-19 patients is short, these ADRs are not restrictive.

**Ototoxicity.** Ototoxicity has been reported both with CQ\(^{53}\) and less frequently with HCQ.\(^{54}\) This ADR may induce hearing loss, tinnitus, vertigo, and disequilibrium. Accordingly, CQ/HCQ ototoxicity may mimic stroke in patients with COVID-19 infection.

Because of these systemic adverse effects related to oral administration of CQ and HCQ, a hypothesis has been suggested that an aerosol formulation of HCQ with a dosage of 2 to 4 mg per inhalation dose, which is one-hundredth of the oral dose, would be considered as an alternative to obtain HCQ therapeutic level in epithelial cells. This low dose formulation with a non-systemic route of administration may minimize adverse drug reactions related to CQ therapy in COVID-19 patients. This novel dosage form might be mostly beneficial in patients with predisposing diseases, elderly groups, and poly-pharmacy patients.\(^{55}\)

**Lopinavir/Ritonavir**

The most common adverse events related to lopinavir/ritonavir are gastrointestinal adverse effects such as diarrhea, nausea, and vomiting. But other serious adverse reactions such as AKI, respiratory failure, or secondary infection were not observed in patients treated with lopinavir/ritonavir.\(^{56}\)

**Tocilizumab**

Tocilizumab might cause vascular disorders such as hypertension. Also, it could induce nervous system disorders such as headache, demyelinating disorders, leukoencephalopathy with cognitive impairment, and peripheral neuropathy.\(^{57}\) A serious adverse effect reported with tocilizumab is increasing the risk of fungal and bacterial infections which should be considered in COVID-19 patients.

Although tocilizumab is not metabolized by the CYP3A4 isoenzyme system, enhanced IL-6 levels had been observed in inflammatory conditions, would inhibit these enzymes, so results in slowing the metabolism of drugs through these pathways. Since CYP3A4 isoenzyme is responsible for the metabolism of many medications, administration of IL-6 inhibitors, such as tocilizumab, could enhance the metabolism of drugs metabolized through the CYP3A4 system such as lopinavir, ritonavir, and atazanavir.

**Corticosteroids**

**Psychosis**

Corticosteroids could induce psychiatric adverse reactions. Corticosteroid-induced psychosis mostly occurs as a dose-dependent adverse effect but idiosyncratic psychotic reactions were also observed.\(^{58-60}\) Since acute psychotic features (ex, delusion and visual or auditory hallucinations) might occur in older patients who have had a stroke,\(^{61}\) pay attention to these adverse reactions of corticosteroids in COVID-19 patients who had developed to ARDS with predisposing cerebrovascular diseases is highly crucial.

**Seizure**

Corticosteroids could induce convulsion through central mineralocorticoid receptors. This ADR is very rare but it should be considered because of its high clinical importance.\(^{62}\) Since seizure is one of the post-stroke complications, so in COVID-19 patients with predisposing cerebrovascular diseases such as stroke, close monitoring during steroid therapy is strongly recommended. The potential mechanism of post-stroke seizure would be the reduction of tonic inhibition.\(^{63}\)

**Anxiety and Agitation**

Corticosteroid consumption could induce mood changes such as anxiety, agitation, and depression.\(^{64}\) Generalized anxiety disorder, agitation, and depression are common post-stroke complications.\(^{65}\) So, neurologists and clinical pharmacists should be aware of these precipitating ADRs in COVID-19 pneumonia patients with ARDS and history of stroke managed with corticosteroids.

**Myopathy**

Steroid myopathy is related to high dose corticosteroid administration and prolonged exposure to steroids. Acute steroid myopathy is a rare but clinically important adverse effect of high dose steroid therapy that presents with...
muscular pain and weakness. Since this adverse reaction might also be occurred in COVID-19 patients, so close patient monitoring during steroid therapy is highly essential.

Investigational Treatments
Umifenovir (Arbidol) could induce adverse effects of dizziness and psychiatric symptoms but generally considered safe and could be well-tolerated. Remdesivir is also a well-tolerated agent with few serious adverse reactions. Favipiravir might rarely induce drug-related psychotic symptoms.

Angiotensin Converting Enzyme II (ACE2) and COVID-19
ACE2 receptor is extensively expressed in various organs such as lungs, intestine, kidneys and blood vessels. It is also presented on the surface of different cells involved in the immune response. The higher circulating amount of ACE2 was also reported in patients with DM, HTN, and cardiovascular disease (CVD). It has been hypothesized that ACEIs and angiotensin receptor blockers (ARBs) may increase the possibility of COVID-19 infection or aggravation of its course. However, the Heart Failure Society of America, the American Heart Association, and also the American College of Cardiology recommended that ACEIs and/or ARBs could be continued in patients with robust indications.

Potential Drug–Drug Interactions (PDDIs)
Based on Infectious Diseases Society of America (IDSA) Guidelines 2020 on the Treatment and Management of Patients with COVID-19 Infection, CQ/HCQ, fixed dose of lopinavir/ritonavir, tocilizumab, and convalescent plasma could be considered in COVID-19 management in the context of clinical trials. Other drugs that are also under investigation are favipiravir and remdesivir for the management of COVID-19 especially in critically ill patients. Some Chinese guidelines also suggest nebulized interferon-alpha and oral umifenovir (Arbidol) for the treatment of COVID-19, also many supportive therapies have been considered. Also, results of recent studies have revealed that teicoplanin and ivermectin would be promising agents but clinical trials are required to confirm their safety and efficacy in COVID-19 pneumonia management. As many off-label treatments of COVID-19 infections are performed by poly pharmacy with the hope of treatment of a cureless disease, investigation of PDDIs becomes more important.

Table 3 demonstrated a list of PDDIs between drugs used in COVID-19 pneumonia management and common drugs that are used in patients with predisposing cerebrovascular disease. According to Table 3, in COVID-19 patients with cerebrovascular disease who are taking clopidogrel, ticagrelor, and NOACs such as rivaroxaban, administering lopinavir/ritonavir and atazanavir are not suitable for COVID-19 management because of the presence of major drug–drug interactions between these drugs. In these patients, interferon-alpha or other antiviral agents such as favipiravir and remdesivir would be better choices to avoid further complications. Cardiovascular drugs have potential major interactions with antiretroviral agents, so they should be considered by clinicians and clinical pharmacists. Suitable dose modification or

Table 3 Potential Drug–Drug Interactions in COVID-19 Patients with Predisposing Cerebrovascular Diseases

| No action needed | Monitor therapy | Avoid combination | Consider therapy modification | No interaction | Coadministration or combination | Coadministration or combination | Coadministration or combination | Coadministration or combination | Coadministration or combination |
|-------------------|-----------------|------------------|-------------------------------|----------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|-------------------------------|
| Aspirin Clopidogrel Cilostazol Dipyridamole Ticagrelor | | | | | | | | | |
| Labetalol Nicardipine Sodium Nitroprusside | | | | | | | | | |
| Iopamidol, Iopromid, Iodixanol | | | | | | | | | |
| Iohexol, Gadolinium-containing (Ionic) | | | | | | | | | |
| Gadoterate Meglumine | | | | | | | | | |
| Iopamidol, Iopromid, Iodixanol | | | | | | | | | |
| Iohexol, Gadolinium-containing (Ionic) | | | | | | | | | |
| Gadoterate Meglumine | | | | | | | | | |

For personal use only.
alternative drug selection should be taken into account in these cases. Possible mechanisms and types of X-category drug–drug interactions and management of these interactions have been shown in Table 4.

**Conclusion**

As it is seen both CQ and HCQ, antiviral agents, and corticosteroids could induce delirium. Delirium occurs very commonly in older hospitalized patients. The frequency of delirium in stroke patients (13%- 48%) is higher than in patients who are admitted to general internal medicine wards (10%-25%). Also, stroke patients have higher mortality and longer hospital stay. Early recognition and prevention of delirium should be considered in patients with stroke and COVID-19 infection. Pharmacological and non-pharmacological strategies should be considered for the management of delirium. In addition, most importantly PDDIs should be monitored and addressed by clinical pharmacists and neurologists. There are anecdotal and published results of increased prevalence of seizure in patients with COVID-19 infection. About 5%-20% of stroke victims may develop to seize. A decreased threshold of seizure in patients with stroke and COVID-19 infection who receive CQ, HCQ, or corticosteroids should be kept in mind. Metabolic disorders such as hypo/hypernatremia, hypo/hyperglycemia, uremia, and hypocalcemia, which

**Table 4 Possible Mechanisms, Types of Interactions, and Management of X-Category Drug–Drug Interactions**

| Types of Interaction | Mechanism of Interaction | Interaction Management |
|----------------------|--------------------------|------------------------|
| Lopinavir/Ritonavir or Atazanavir plus Clopidogrel | Pharmacokinetic | Ritonavir and atazanavir might inhibit clopidogrel (a pro-drug) metabolism to its active metabolite so it result in the diminished antiplatelet activity. | Avoid combinations and consider possible alternatives. |
| Lopinavir/Ritonavir or Atazanavir plus Ticagrelor | Pharmacokinetic | Strong CYP3A4 inhibitors would enhance the serum concentration of ticagrelor and reduce the serum concentration of its active metabolites. | Avoid a combination of ticagrelor with strong CYP3A4 inhibitors and consider alternatives. |
| Lopinavir/Ritonavir or Atazanavir plus Rivaroxaban | Pharmacokinetic | Since rivaroxaban is a substrate for both CYP3A4 isozyme and P-gp, concomitant administration of this drug with strong inhibitors of CYP3A4 and inhibitors of P-gp may enhance the serum concentration of rivaroxaban and risk of major bleeding. | Avoid a combination of rivaroxaban with strong CYP3A4 inhibitors and P-gp inhibitors. |
| Lopinavir/Ritonavir or Atazanavir plus Apixaban | Pharmacokinetic | These concomitant administrations might result in inhibition of CYP3A4 mediated metabolism and P-gp induced efflux of apixaban which may cause enhanced serum concentration of apixaban and bleeding complications. | A combination of apixaban with strong CYP3A4 inhibitors and P-gp inhibitors is contraindicated. |
| Lopinavir/Ritonavir or Atazanavir plus Edoxaban | Pharmacokinetic | Inhibitors of P-gp/ABCB1 might enhance the C_{max}, AUC, and anticoagulant effect of edoxaban. | A combination of edoxaban with P-gp/ABCB1 inhibitors should be avoided or dose adjustment should be considered in patients with venous thromboembolism. No dosage modification is available in patients with non-valvular atrial fibrillation. |
| Lopinavir/Ritonavir or Atazanavir plus Dabigatran etexilate | Pharmacokinetic | Inhibitors of P-gp/ABCB1 could enhance the serum concentration of active metabolites of dabigatran etexilate, which is a pro-drug agent. These drug–drug interactions would be significantly precipitated in patients with moderate to severe renal failure. | Avoid combination or consider therapy modification. Dose adjustment may also be considered according to the patients’ renal function, dabigatran etexilate indications, and labeling recommendations. |

**Notes:**  
^a^Cytochrome P450 (CYP) 3A4. ^b^glycoprotein. ^c^ATP-binding cassette sub-family B member 1. ^d^Max serum concentration. ^e^Area under the curve.
decrease the threshold of seizure activity, should be corrected. The probability of non-convulsive status epilepticus as a cause of altered mental function in the patients with COVID-19 infection should also be considered. As patients with COVID-19 infection and stroke may experience prolonged ICU admission, they are susceptible to critical illness myopathy, neuropathy, or polynuromyopathy and consequently prolonged mechanical ventilation. Among drugs that have been used for treatments of COVID-19 infection, CQ, HCQ, antivirals, and corticosteroids may induce myopathy and/or neuropathy. Therefore, ADR of these drugs may contribute to failure to wean from ventilators.

As conclusion, in patients with stroke and COVID-19 infection who are taking drugs according to trials or humanitarian use, it is highly recommended to monitor patients to avoid the occurrence or progression of cardiac arrhythmias, delirium, seizure, myopathy and/or neuropathy. In addition, PDDIs of anti-COVID-19 drugs with tPA, anticoagulants, antiaggregants, statins, antihypertensive agents, and iodine-contrast agents should be considered. The most harmful PDDIs were interaction of Lopinavir/Ritonavir or Atazanavir with clopidogrel, prasugrel, and NOACs. In these situations, early intervention of neurologists and clinical pharmacists is essential to avoid further disabling toxicity complications.

Author Contributions
All authors made substantial contributions to conception and design, acquisition of data, or analysis and interpretation of data; took part in drafting the article or revising it critically for important intellectual content; gave final approval of the version to be published; and agree to be accountable for all aspects of the work.

Disclosure
The authors have no conflict of interest.

References
1. Guan W-J, Liang W-H, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. doi:10.1183/13993003.00547-2020
2. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069. doi:10.1001/jama.2020.1585
3. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020.
4. Bernheim A, Mei X, Huang M, et al. Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. Radiology. 2020;200463.
5. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemostasis. 2020;18(4):844–847. doi:10.1111/jth.14768
6. Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273. doi:10.1038/s41586-020-2022-7
7. Deng S-Q, Peng H-J. Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. J Clin Med. 2020;9(2):575. doi:10.3390/jcm9020575
8. Group C-S. Characteristics of COVID-19 Patients Dying in Italy: Report Based on Available Data on March 20th, 2020. Rome, Italy: Instituto Superiore Di Sanita; 2020.
9. Jin H, Hong C, Chen S, et al. Consensus for prevention and management of coronavirus disease 2019 (COVID-19) for neurologists. Stroke Vasc Neurol. 2020;svn-2020-00382.
10. Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. ChinaXiv Preprint. 2020.
11. Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N Engl J Med. 2020;382(17): e38. doi:10.1056/NEJMct2007575
12. Vazin A, Fereidooni M. Determining frequency of prescription, administration and transcription errors in internal intensive care unit of Shahid Faghihi Hospital in Shiraz with direct observation approach. Iran J Pharm Sci. 2012;8(3):189–194.
13. Namazi S, Borhani-Haghighi A, Karimzadeh I. Adverse reactions to antiepileptic drugs in epileptic outpatients: a cross-sectional study in Iran. Clin Neuropharmacol. 2011;34(2):79–83. doi:10.1097/WNF.0b013e318210eec0
14. Namazi S, Pourhamedi S, Borhani-Haghighi A, Roosta S. Incidence of potential drug-drug interaction and related factors in hospitalized neurological patients in two Iranian teaching hospitals. Iran J Med Sci. 2014;39(6):515.
15. Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with inhospital death of patients with COVID-19. Kidney Int. 2020.
16. Yang L, Xing G, Wang L, et al. Acute kidney injury in China: a cross-sectional survey. The Lancet. 2015;386(10002):1465–1471. doi:10.1016/S0140-6736(15)00344-X
17. Arnold J, Ng KP, Sims D, Gill P, Cockwell P, Ferro C. Incidence and impact on outcomes of acute kidney injury after a stroke: a systematic review and meta-analysis. BMC Nephrol. 2018;19(1):283. doi:10.1186/s12882-018-1085-0
18. Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res. 2020;177:104762. doi:10.1016/j.antiviral.2020.104762
19. Wang Y, Zhu LQ. Pharmaceutical care recommendations for antiviral treatments in children with coronavirus disease 2019. World J Pediatr. 2020. doi:10.1007/s12519-020-00353-5
20. Available from: https://epidemio.wiv-isp.be/IStudio/Svn-2020-000382.svn-2020-000382. doi:10.1056/NEJMc2007575
21. Kumar GN, Jayanti VK, Johnson MK, et al. Metabolism and kinetics and summary of efavirenz and atazanavir. J Clin Pharmacol Ther. 2020;55(4):105933. doi:10.1002/jctb.2020.105933
Ghasemiyeh et al

26. Kato A, Watanabe T, Yamaizaki M, Doki T, Suzuki M. IL-6R distribution in normal human and cynomolgus monkey tissues. *Regul Toxicol Pharmacol.* 2009;53(1):46–51. doi:10.1016/j.yrtph.2008.10.007

27. Wilson APR. Clinical pharmacokinetics of teicoplanin. *Clin Pharmacokinet.* 2000;39(3):167–183. doi:10.2165/00003088-20003903-00001

28. Mai NTH, Day NP, Van Chuong L, et al. Post-malaria neurological syndrome. *The Lancet.* 1996;348(9032):917–921. doi:10.1016/S0140-6736(96)60409-2

29. O'Shaughnessy TJ, Zim B, Ma W, et al. Acute neuropathologic action of chloroquine on cortical neurons in vitro. *Brain Res.* 2003;959(2):280–286. doi:10.1016/S0006-8993(02)03763-0

30. Simooya OO. *Antiprotozoal Drugs. Side Effects of Drugs Annual.* 36. Elsevier; 1992:393–400.

31. Tristano AG, Falcón L, Willson M, de Oca IM. Seizure associated with chloroquine therapy in a patient with systemic lupus erythematosus. *Rheumatol Int.* 2004;24(5):315–316. doi:10.1007/s00296-003-0435-8

32. Hughes JT, Oxbury EM, Whitby JC. Chloroquine myopathy. *QJM.* 1971;40(1):85–93.

33. Abdel-Hamid H, Oddis CV, Lacomas D. Severe hydroxychloroquine myopathy. *Muscle Nerve.* 2008;38(3):1206–1210. doi:10.1002/mus.20919

34. Chen C, Huang J, Cheng Z, et al. Favipiravir versus Arbidol for COVID-19: a randomized clinical trial. *medRxiv.* 2020.

35. Perantie DC, Brown ES. Corticosteroids, immune suppression, and psychosis. *Curr Psychiatry Rep.* 2002;4(3):171–176. doi:10.1007/s11920-002-0023-8

36. Brown ES, Khan DA, Nejtek V A. The psychiatric side effects of corticosteroids. *Ann Allergy Asthma Immunol.* 1999;83(6):495–504. doi:10.1016/S1081-1206(17)32658-X

37. Ling MH, Perry PJ, Tsuang MT. Side effects of corticosteroid therapy: psychiatric aspects. *Arch Gen Psychiatry.* 1981;38(4):471–477. doi:10.1001/archpsyc.1981.01870920105011

38. Walker AE, Adamkiewicz J. Pseudotumor cerebri associated with prolonged corticosteroid therapy: reports of four cases. *JAMA.* 1964;188(9):779–784. doi:10.1001/jama.1964.03060350005001

39. Liu GT, Kay MD, Bienfang DC, Schatz NJ. Pseudotumor cerebri associated with chloroquine therapy in a patient with systemic lupus erythematosus. *Seizure* 2009;18(10):675–680. doi:10.1016/j.seizure.2009.04.002

40. Levin OS, Polunina AG, Demyanova MA, Isaev FV . Steroid myopathy in patients with chronic respiratory diseases. *S0002-9394(14)73145-9

41. Bird SJ, Sladky JT. Brief communications: Corticosteroid-responsive dominantly inherited neuropathy in childhood. *Neurology.* 2013;81(2):196–197. doi:10.1212/WNL.0b013e3182952507

42. Rebolleda G, Pérez-López M, Casas-Llera P, Contreras I, Miñóz-Negrete FJ. Visual and anatomical outcomes of non-articiler anterior ischemic optic neuropathy with high-dose systemic corticosteroids. *Graefe's Arch Clin Exp Ophthalmol.* 2013;251(1):255–260. doi:10.1007/s00417-012-1995-7

43. Parmar R, Valvi C, Kamat JR, Vaswani R. Chloroquine induced parkinsonism. *J Postgrad Med.* 2000;46(1):29.

44. Busari OA, Fadare J, Agboula S, Gabriel O, Elegbede O, Oladosu Y. Chloroquine-induced acute dystonic reactions after a standard therapeutic dose for uncomplicated malaria. *Sultan Qaboos Univ Med J.* 2013;13(3):E476. doi:10.12818/1303279

45. Biswas PK, Sen D, Majumdar R. Psychosis following chloroquine ingestion: a 10-year comparative study from a malaria-hyperendemic district of India. *Gen Hosp Psychiatry.* 2014;36(2):181–186. doi:10.1016/j.genhosppsych.2013.07.012

46. Luijckx G, de Krom M, Takx-Kohlen B. Does chloroquine cause seizures? Presentation of three new cases and a review of the literature. *Seizure.* 1992;1(3):183–185. doi:10.1016/1059-1311(92)90023-T

47. Krezminski P, Lesiak A, Narbutt J. Seizures as a rare adverse effect of chloroquine therapy in systemic lupus erythematosus patients: a case report and literature survey. *Advan Dermatol Allerg/ Postepy Dermatologii I Alergologii.* 2018;35(4):429. doi:10.5114/adap.2018.77675

48. Khosa S, Khlanou N, Khosa GS, Mishra SK. Hydroxychloroquine-induced autophagic vacuolar myopathy with mitochondrial abnormalities. *Neuropathology.* 2018;38(6):646–652. doi:10.1111/neup.12520

49. Baguet J, Tremel F, Fabre M. Chloroquine cardiomyopathy with conduction disorders. *Heart.* 1999;81(2):221–222. doi:10.1136/hrt.81.2.221

50. Jafari A, Dadkhahfar S, Persh S. Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatments. *Crit Rev Oncol Hematol.* 2020;102982.

51. Giudicessi JR, Noseworthy PA, Friedman PA, Ackerman MJ, editors. Urgent guidance for navigating and circumventing the QTc-prolonging and torsadogenic potential of possible pharmacotherapies for coronavirus disease 19 (COVID-19). Mayo Clinic Proceedings; 2020: Elsevier.
66. Sun L-Y, Chu X-L. Acute myopathy following intra-muscular injection of compound betamethasone: A case report. Medicine. 2017;96:34.
67. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;1–8.
68. Fang L, Karakiulakis G, Roth M. Antihypertensive drugs and risk of COVID-19? Authors’ reply. Lancet Respir Med. 2020.
69. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. doi:10.1016/S2213-2600(20)30116-8
70. Association STAH, America HFSo, Cardiology ACo. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician.
71. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58–60. doi:10.5582/ddt.2020.01012
72. Jin Y-H, Cai L, Cheng Z-S, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Military Med Res. 2020;7(1):4. doi:10.1186/s40779-020-0233-6
73. Ghasemiyeh P, Mohammadi-Samani S. Iron chelating agents: promising therapeutic agents in severe cases of COVID-19? Trends Pharmacol Sci. 2020;6(2):65–66.
74. Baron SA, Devaux C, Colson P, Raoul D, Rolain J-M. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19? Int J Antimicrob Agents. 2020;55(4):105944. doi:10.1016/j.ijantimicag.2020.105944
75. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res. 2020;104787.
76. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55(3):105924. doi:10.1016/j.ijantimicag.2020.105924
77. Bansal M. Cardiovascular disease and COVID-19. Diabetes Metabol Syndr. 2020.
78. Lipowski Z. Transient cognitive disorders (delirium, acute confusional states) in the elderly. Psychos Med Liaison Psychiatry. 1983;289–306.
79. Oldenbeuving A, De Kort P, Jansen B, Roks G, Kappelle L. Delirium in acute stroke: a review. Int J Stroke. 2007;2(4):270–275. doi:10.1111/j.1747-4949.2007.00163.x
80. Connolly ES Jr, Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2012;43(6):1711–1737. doi:10.1161/STR.0b013e3182587839
81. Karimi N, Sharifi Razavi A, Rouhani N. Frequent convulsive seizures in an adult patient with COVID-19: a case report. Iran Red Crescent Med J. In Press.
82. Silverman IE, Restrepo I, Mathews GC. Poststroke seizures. Arch Neurol. 2002;59(2):195–201. doi:10.1001/archneur.59.2.195
83. Shepherd S, Batra A, Lerner DP. Review of critical illness myopathy and neuropathy. Neurohospitalist. 2017;7(1):41–48. doi:10.1177/194187441663279